In an interview with Moneycontrol, Kedar Upadhye, Global Chief Financial Officer of Cipla, talked about the company's strategy going forward.
India is a sizeable market for us. Our growth story is intact in our core markets. I am not unduly concerned about growth trajectories within our core markets, said Umang Vohra, MD & Global CEO of Cipla.
In an interview with CNBC-TV18, Kedar Upadhye, Group CFO of Cipla spoke about the results and his outlook for the company.
The US remains the largest market in the world and they look at it as an attractive opportunity, Umang Vohra, MD & Global CEO, Cipla.
In an interview to CNBC-TV18's Ekta Batra and Vikas Dandekar, the Executive Chairman of Torrent Pharma, Samir Mehta spoke about the rationale behind the deal and where it would take the company in the Indian pharmaceutical market.
In an interview to CNBC-TV18, Anmol Ganjoo, Director of JM Financial Institutional Securities spoke about his latest report on Indian pharmaceutical space. Ganjoo has written on multiple stocks as well as the entire framework of the pharmaceutical space.
In an interview to CNBC-TV18, Pravin Herlekar, CMD of Omkar Speciality Chemicals discussed the company's Q1 performance.
In an interview to CNBC-TV18, Chander Agarwal, MD & CEO, TCI Express spoke about the results and his outlook for the company.
Umang Vohra of Cipla reasoned that almost 80 percent of the drugs sold by Cipla in the US market are manufactured in the US itself. He said it will not be a challenge to manufacture all its supplies in the US itself if asked to do so by authorities.
Adar Poonawala, CEO of Serum Institute, believes that a bigger partnership with Cipla will create a big Indian conglomerate. However, he added that the Cipla promoters currently have no plans for a merger and acquisition.
Initiatives are underway to normalise operations and the management is committed to making its EBITDA trajectory more sustainable in FY17, says Umang Vora, Global COO, Cipla.
In the last five months, plants of nine Indian pharmaceutical companies - Cipla, Dr Reddy‘s, Sun Pharma, Cadila, Lupin and Natco Pharma.- have come under the US Food and Drug Administration (FDA) scanner.
When asked about the Cipla Indore facility, which has come under the USFDA scanner for manufacturing norms violations, Talati reassures that the facility is not a major contributer to Cipla earnings. Hence this news, he feels should not affect sales.
In an interview with CNBC-TV18, Umang Vohra, COO of Cipla said that the company‘s current growth guidance did not include this merger and it will be a part of it in the next fiscal.
Jaideep Gogtay, Clinical Head at Cipla pointed out that in India the cost of treatment of Hepatitis C ranges between Rs 75,000 to Rs 1.5 lakh per patient, depending on the type of virus and the intensity.
Cipla Global Chief Executive Officer Subhanu Saxena said both acquisitions would add to Cipla's earnings from Day One, and that the acquisition would give the company a strong platform to accelerate growth in US.
The pharma major's MD and CEO Subhanu Saxena says the company is aiming at achieving a growth of 70-80 percent growth without making any major acquisitions in the near future.
Calling consumer healthcare to be an exciting space for the company, Chandru Chawla, the head of Cipla, New Ventures says: "Consumer health market in India is upwards of USD 4 billion today and is growing at a very high double digit."
The company has 20 facilities across the globe with portfolio of more than 200 products in 138 countries.
Billionnaire Cyrus Poonawalla, founder of the world‘s biggest vaccine maker Serum Institute, has told CNBC-TV18 that after the company tied up with drugmaker Cipla to sell its vaccines in Europe late last year, Serum is now exploring the option of merging with it.
After tying up with drugmaker Cipla to market its products last year, the Poonawalla Group's Serum Institute, the world's largest vaccine maker, is considering the option of merging with it.
As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.
The company's CEO, Subhanu Saxena, in an exclusive conversation with CNBC-TV18's Archana Shukla says the focus is on building the company for the long term.
On the days to come, Yusuf Hamied, chairman, Cipla, says the pharma major may open units in foreign countries just like its peers.
Rajesh Garg, global chief financial officer, Cipla, told CNBC-TV18 that operating profits were impacted in the absence of anti-depressant Escitalopram sales in the US, and higher sales of anti-retroviral (ARV) drugs, where profit margins are low.
